- Home
- ABCL
as of 03-13-2026 3:46pm EST
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
| Founded: | 2012 | Country: | Canada |
| Employees: | N/A | City: | VANCOUVER |
| Market Cap: | 910.0M | IPO Year: | 2020 |
| Target Price: | $7.75 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.49 | EPS Growth: | 10.91 |
| 52 Week Low/High: | $1.89 - $6.51 | Next Earning Date: | 05-26-2026 |
| Revenue: | $75,128,000 | Revenue Growth: | 160.56% |
| Revenue Growth (this year): | -57.83% | Revenue Growth (next year): | 16.59% |
| P/E Ratio: | -7.08 | Index: | N/A |
| Free Cash Flow: | -174067000.0 | FCF Growth: | N/A |
AI-Powered ABCL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of AbCellera Biologics Inc. (ABCL)
Chief Financial Officer
Avg Cost/Share
$3.42
Shares
42,600
Total Value
$145,692.00
Owned After
195,600
SEC Form 4
10% Owner
Avg Cost/Share
$3.44
Shares
38,000
Total Value
$130,720.00
Owned After
56,134,097
SEC Form 4
10% Owner
Avg Cost/Share
$3.27
Shares
177,457
Total Value
$580,284.39
Owned After
56,134,097
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Booth Andrew | ABCL | Chief Financial Officer | Feb 27, 2026 | Buy | $3.42 | 42,600 | $145,692.00 | 195,600 | |
| Thermopylae Holdings Ltd. | ABCL | 10% Owner | Feb 27, 2026 | Buy | $3.44 | 38,000 | $130,720.00 | 56,134,097 | |
| Thermopylae Holdings Ltd. | ABCL | 10% Owner | Feb 26, 2026 | Buy | $3.27 | 177,457 | $580,284.39 | 56,134,097 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 24, 2026 · 100% conf.
Q4 2025 Earnings
8-K SELLFeb 24, 2026 · 100% conf.
1D
-5.86%
$3.05
5D
-8.39%
$2.97
20D
-10.45%
$2.90
abcl-202602240001703057falseVancouverBC00017030572026-02-242026-02-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): February 24, 2026
AbCellera Biologics Inc. (Exact name of registrant as specified in its charter)
British Columbia001-39781Not Applicable (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification Number)
150 W 4th Avenue Vancouver, BC
V5Y 1G6
(Address of registrant’s principal executive office)(Zip code)
(604) 559-9005 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered Common sharesABCLThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition On February 24, 2026, AbCellera Biologics Inc. (the “Company”), issued a press release announcing its financial and operational results for the year ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.
Item 7.01 Regulation FD In connection with its earnings call on February 24, 2026, to discuss its results for the year ended December 31, 2025, the Company will utilize a corporate presentation, a copy of which is furnished herewith as Exhibit 99.2. The information in Items 2.02 and 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description 99.1Press Release issued by AbCellera Biologics Inc. on February 24, 2026.
99.2Corporate Presentation.
104Cover Page Interactive Data File (embedded as Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 24, 2026ABCELLERA BIOLOGICS INC.
By:/s/ Carl L. G. Hansen Carl L. G. Hansen, Ph.D. Chief Executive Officer and Director (Principal Executive Officer)
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
Q3 2025 Earnings
8-KNov 6, 2025
abcl-202511060001703057falseVancouverBC00017030572025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 6, 2025
AbCellera Biologics Inc. (Exact name of registrant as specified in its charter)
British Columbia001-39781Not Applicable (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification Number)
150 W 4th Avenue Vancouver, BC
V5Y 1G6
(Address of registrant’s principal executive office)(Zip code)
(604) 559-9005 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered Common sharesABCLThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition On November 6, 2025, AbCellera Biologics Inc. (the “Company”), issued a press release announcing its financial and operational results for the quarter ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.
Item 7.01 Regulation FD Disclosure In connection with its earnings call on November 6, 2025, to discuss its results for the quarter ended September 30, 2025, the Company will utilize a corporate presentation, a copy of which is furnished herewith as Exhibit 99.2. The information in Items 2.02 and 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description 99.1Press Release issued by AbCellera Biologics Inc. on November 6, 2025.
99.2Corporate presentation.
104Cover Page Interactive Data File (embedded as Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 6, 2025
ABCELLERA BIOLOGICS INC.
By:/s/ Carl L. G. Hansen Carl L. G. Hansen, Ph.D. Chief Executive Officer and Director (Principal Executive Officer)
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
Q2 2025 Earnings
8-KAug 7, 2025
abcl-202508070001703057falseVancouverBC00017030572025-08-072025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 7, 2025
AbCellera Biologics Inc. (Exact name of registrant as specified in its charter)
British Columbia001-39781Not Applicable (State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification Number)
150 W 4th Avenue Vancouver, BC
V5Y 1G6
(Address of registrant’s principal executive office)(Zip code)
(604) 559-9005 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered Common sharesABCLThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition On August 7, 2025, AbCellera Biologics Inc. (the “Company”), issued a press release announcing its financial and operational results for the quarter ended August 7, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.
Item 7.01 Regulation FD Disclosure In connection with its earnings call on August 7, 2025, to discuss its results for the quarter ended June 30, 2025, the Company will utilize a corporate presentation, a copy of which is furnished herewith as Exhibit 99.2. The information in Items 2.02 and 7.01 of this Form 8-K (including the exhibits attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.
Item 9.01 Financial Statements and Exhibits (d)Exhibits
Exhibit No.Description 99.1Press Release issued by AbCellera Biologics Inc. on August 7, 2025.
99.2Corporate presentation.
104Cover Page Interactive Data File (embedded as Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 7, 2025
ABCELLERA BIOLOGICS INC.
By:/s/ Carl L. G. Hansen Carl L. G. Hansen, Ph.D. Chief Executive Officer and Director (Principal Executive Officer)
Compare ABCL vs Leading Stocks
See how ABCL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ABCL AbCellera Biologics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.